Other official information and services: www.belgium.be  belgium

Cardiovascular system drugs

  • Key figures
  •  Data
  • Graphics
  • Comments
PRESCRIBERS
Main prescribers: General practitioners 82.04%
INSURED CONSUMERS
% of insured consumers 27.94%
Median age 67 years
Max/min ratio of the median age (by district) 1.08
Percentage of women 52.57%
Ratio Preferential scheme/General scheme 1.16
Coefficient of variation (2022) 5.77
Max/min ratio of % of insured consumers (by district) 1.21
CONSUMPTION
Annual consumption (DDD) 2,046,966,452
Consumption of DDD (per 100,000 insured persons) 17,785,943.51
% DDD issued outside the insurance (approximate) 3.63%
Average annual consumption per insured consumer (DDD) 636.66
% of insured consumers with > 3 times the average consumption 3,89%
Coefficient of variation 2013-2015 8.82
Coefficient of variation 2020-2022 7.77
Trend 2013-2022 -0.87%
Trend 2013-2019 -1.26%
Trend 2019-2022 -0.08%
DIRECT EXPENDITURE (DDD)
Annual expenditure charged to the insurance 398,626,902€
Average annual expenditure per insured person 34.64 €
Average patient share per insured consumer 20.24%
Max/min ratio of expenditure per insured person (by disctrict) 1.48
% “Low-cost” medication 87.19%
Trend 2013-2022 -4.61%
Trend 2019-2022 0.96%


On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

+ - ATC codes selected for analysis Click to collapse

CODES (ATC-5) LABELS
C01AA DIGITALIS GLYCOSIDES
C01BA ANTIARRHYTHMICS, CLASS IA
C01BB ANTIARRHYTHMICS, CLASS IB
C01BC ANTIARRHYTHMICS, CLASS IC
C01BD ANTIARRHYTHMICS, CLASS III
C01BG OTHER CLASS I ANTIARRHYTHMICS
C01CA ADRENERGIC AND DOPAMINERGIC AGENTS
C01CE PHOSPHODIESTERASE INHIBITORS
C01CX OTHER CARDIAC STIMULANTS
C01DA ORGANIC NITRATES
C01DX OTHER VASODILATORS USED IN CARDIAC DISEASES
C01EA PROSTAGLANDINS
C01EB OTHER CARDIAC PREPARATIONS
C02AA RAUWOLFIA ALKALOIDS
C02AB METHYLDOPA
C02AC IMIDAZOLINE RECEPTOR AGONISTS
C02CA ALPHA-ADRENORECEPTOR ANTAGONISTS
C02CC GUANIDINE DERIVATIVES
C02DA THIAZIDE DERIVATIVES
C02DB HYDRAZINOPHTHALAZINE DERIVATIVES
C02DC PYRIMIDINE DERIVATIVES
C02DD NITROFERRICYANIDE DERIVATIVES
C02DG GUANIDINE DERIVATIVES
C02KD SEROTONIN ANTAGONISTS
C02KX OTHER ANTIHYPERTENSIVES
C03AA THIAZIDES, PLAIN
C03AB THIAZIDES AND POTASSIUM IN COMBINATION
C03BA SULFONAMIDES, PLAIN
C03CA SULFONAMIDES, PLAIN
C03DA ALDOSTERONE ANTAGONISTS
C03DB OTHER POTASSIUM-SPARING AGENTS
C03EA LOW-CEILING DIURETICS AND POTASSIUM-SPARING AGENTS
C03EB HIGH-CEILING DIURETICS AND POTASSIUM-SPARING AGENTS
C03XA VASOPRESSIN ANTAGONISTS
C04AA 2-AMINO-1-PHENYLETHANOL DERIVATIVES
C04AB IMIDAZOLINE DERIVATIVES
C04AC NICOTINIC ACID AND DERIVATIVES
C04AD PURINE DERIVATIVES
C04AE ERGOT ALKALOIDS
C04AX OTHER PERIPHERAL VASODILATORS
C05AA CORTICOSTEROIDS
C05AD LOCAL ANESTHETICS
C05AE MUSCLE RELAXANTS
C05AX OTHER AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05BA HEPARINS OR HEPARINOIDS FOR TOPICAL USE
C05BB SCLEROSING AGENTS FOR LOCAL INJECTION
C05BX OTHER SCLEROSING AGENTS
C05CA BIOFLAVONOIDS
C05CX OTHER CAPILLARY STABILIZING AGENTS
C07AA BETA BLOCKING AGENTS, NON-SELECTIVE
C07AB BETA BLOCKING AGENTS, SELECTIVE
C07AG ALPHA AND BETA BLOCKING AGENTS
C07BA BETA BLOCKING AGENTS, NON-SELECTIVE, AND THIAZIDES
C07BB BETA BLOCKING AGENTS, SELECTIVE, AND THIAZIDES
C07CA BETA BLOCKING AGENTS, NON-SELECTIVE, AND OTHER DIURETICS
C07CB BETA BLOCKING AGENTS, SELECTIVE, AND OTHER DIURETICS
C07DB BETA BLOCKING AGENTS, SELECTIVE, THIAZIDES AND OTHER DIURETICS
C07FB BETA BLOCKING AGENTS, SELECTIVE, AND OTHER ANTIHYPERTENSIVES
C08CA DIHYDROPYRIDINE DERIVATIVES
C08DA PHENYLALKYLAMINE DERIVATIVES
C08DB BENZOTHIAZEPINE DERIVATIVES
C08EA PHENYLALKYLAMINE DERIVATIVES
C08EX OTHER NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
C09AA ACE INHIBITORS, PLAIN
C09BA ACE INHIBITORS AND DIURETICS
C09BB ACE INHIBITORS AND CALCIUM CHANNEL BLOCKERS
C09BX ACE INHIBITORS, OTHER COMBINATIONS
C09CA ANGIOTENSIN II ANTAGONISTS, PLAIN
C09DA ANGIOTENSIN II ANTAGONISTS AND DIURETICS
C09DB ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS
C09DX ANGIOTENSIN II ANTAGONISTS, OTHER COMBINATIONS
C09XA RENIN-INHIBITORS
C10AA HMG COA REDUCTASE INHIBITORS
C10AB FIBRATES
C10AC BILE ACID SEQUESTRANTS
C10AD NICOTINIC ACID AND DERIVATIVES
C10AX OTHER LIPID MODIFYING AGENTS
C10BA COMBINATIONS OF VARIOUS LIPID MODIFYING AGENTS
C10BX LIPID MODIFYING AGENTS IN COMBINATION WITH OTHER DRUGS

The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.

Click below to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.

Cardiovascular system drugs (2022)

+ - Population selection Click to collapse

No selection

+ - Analysis period Click to collapse

2022

  • ATC codesATC codes
  • Age Sex CVAge, sex and CV
  • Rates by sexRates by sex
  • Reimbursement rateReimbursement rate
  • TrendsTrends by region
  • Trends breakTrends break
  • Dot PlotDot Plot
  • Funnel PlotFunnel plot
  • Provincial consumptionDDD per patient by province
  • DDD patientQuantity per patient
  • MapDistribution map
  • Low-costLow-cost DDD

WE ARE INTERESTED IN YOUR OPINION

Do you have any experience in this area ? We listen to you !

Send us an email

   Download the full report
 Download the methodology